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STRUCTURAL CHARACTERISATION OF THE LEISHMANIA
MAJOR ORTHOLOGUES OF MACROPHAGE MIGRATION
INHIBITORY FACTOR (MIF)
Julia M. Richardson1, Lesley S. Morrison2, Nicholas D. Bland2,3, Sandra Bruce1, Graham H.
Coombs2,4, Jeremy C. Mottram2, and Malcolm D. Walkinshaw1
1Structural Biochemistry Group, School of Biological Sciences, The King’s Buildings, University of
Edinburgh, Mayfield Road, Edinburgh EH9 3JR, Scotland. 2Wellcome Centre for Molecular
Parasitology and Division of Infection & Immunity, Faculty of Biomedical and Life Sciences,
Glasgow Biomedical Research Centre, 120 University Place, Glasgow, G12 8TA, Scotland.
Abstract
Leishmania major, an intracellular parasitic protozoon that infects, differentiates and replicates
within macrophages, encodes two closely related MIF-like proteins, which have only ~20% amino
acid identity with mammalian MIF. Recombinant L. major MIF1 and MIF2 have been expressed
and the structures, resolved by X-ray crystallography, show a trimeric ring architecture similar to
mammalian MIF but with some structurally distinct features. LmjMIF1, but not LmjMIF2, has
tautomerase activity, indicating that the LmjMIFs have evolved potentially different biological
roles. This is further demonstrated by the differential life cycle expression of the proteins.
LmjMIF2 is found in all life cycle stages whereas LmjMIF1 is found exclusively in amastigotes,
the intracellular stage responsible for mammalian disease. The findings are consistent with
parasite MIFs modulating or circumventing the host macrophage response and thereby promoting
parasite survival, however analysis of the L. braziliensis genome showed that this species lacks
intact MIF genes - highlighting that MIF is not a virulence factor in all species of Leishmania.
Parasites have adopted many strategies to avoid or subvert their hosts’ immune responses
including antigenic variation (1), signalling subversion (2) and immune evasion genes (3).
Leishmania parasites are obligate intracellular pathogens and the causative agents of
leishmaniases. The form and severity of the disease ranges from relatively mild dermal
lesions to often fatal visceral infection depending on the infecting Leishmania species and
the immune status of the host (4). Leishmania enter macrophages by receptor-mediated
endocytosis (5) where they differentiate into amastigotes. A number of strategies are
employed by the amistagotes to survive within parasitophorous vacuoles in host
macrophages, including inhibition of NO production, hydrolytic enzymes and calcium
chelation (6).
During the annotation of the L. major genome (7), two genes in tandem (LmjMIF1 and
LmjMIF2) were identified that encode proteins related to mammalian Macrophage
Migration Inhibitory Factor (MIF), which is a major mediator of inflammatory processes
(8). Increased serum levels of MIF contribute to a plethora of auto-immune diseases
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including rheumatoid arthritis (9), type 2 diabetes (10) and colitis (11). Conversely, knock-
out experiments in mice have shown that normal levels of MIF are required for the
resolution of infections by Salmonella typhimurium (12), Mycobacterium tuberculosis (13),
the helminth parasite Taenia crassiceps (14) and L. major (15). Macrophage activation by
IFN-γ is prevented in MIF knockout mice, so that mice normally resistant to L. major
develop non-healing leishmaniasis (15). Homologues of MIF are found in all mammalian
genomes and some helminth parasites, such as Trichinella spiralis (16), Ancylostoma
ceylanicum (17) and Brugia malayi (18). Helminth MIF-like proteins are postulated to
modify host immune responses thus promoting parasite survival (19). Protozoan parasites
including Plasmodium falciparum, P. berghei (20), and Eimeria species (21) also have
characterised MIF orthologues that are released by the parasites to modulate the host
immune system (22). MIF-like proteins are notably absent from African trypanosomes,
which are closely related to Leishmania but do not infect macrophages.
There are now over 30 X-ray structures of MIF available from 8 species including, human
(23), rat (24), mouse (25), frog (26) and the parasites Brugia malayi (27) and L. major (28)
and this study). The trimeric architecture is maintained in all structures. Sequence identities
among mammalian MIF sequences are high (above 85%) however this drops to 20-27%
identity between the human and protozoan Leishmania and Plasmodium sequences. All of
the structurally characterised MIF sequences show keto-enol tautomerase activity with
model substrates like p-hydroxyphenylpyruvate and D-dopachrome, though the biological
relevance of this well characterised activity is still unknown. Small molecule tautomerase
inhibitors of mammalian MIF (29) are being developed for treatment of inflammatory
diseases such as rheumatoid arthritis (30). Mammalian MIFs also have an oxidoreductase
activity that is dependant on a CxxC thioredoxin-like motif. This motif is also implicated in
the intracellular interaction of mammalian MIF with Jab-1, the catalytic subunit of the COP9
signalosome (31).
In this work we describe the X-ray structures of LmjMIF1 and LmjMIF2 and compare these
structures with the known mammalian MIF structures. The possible biological roles of the
two isoforms are discussed in relation to their structures and to their different enzyme
activities.
EXPERIMENTAL PROCEDURES
Parasites
Leishmania major Friedlin (MHOM/JL/80/Friedlin) and Leishmania braziliensis (MHOM/
BR/75M2904) were grown as promastigotes in modified Eagle’s medium (designated
HOMEM medium) supplemented with 10% heat inactivated foetal calf serum (FCS). L.
major metacyclic promastigotes were isolated from stationary phase culture by agglutination
of promastigote cells with peanut lectin as previously described (32). Lesion amastigotes
were purified as previously described (33).
Multiple sequence alignment and phylogenetic reconstruction of MIF proteins
MIF-like protein sequences were identified by a BlastP search of Genbank at NCBI (http://
www.ncbi.nlm.nih.gov/) using human MIF (CAG28572) as the query sequence. 60
sequences with significant blast scores were aligned using Tcoffee Expresso (http://
tcoffee.vital-it.ch/cgi-bin/Tcoffee/tcoffee_cgi/index.cgi) using default settings
(supplementary data 2). This alignment was subsequently used to generate a neighbour-
joining phylogenetic tree using Mega 3.1 (http://www.megasoftware.net/). An unrooted
circular tree lacking bootstrap values has been included in Figure 1, whereas a more detailed
phylogram including percentage bootstrap values is included in supplementary data 3.
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Cloning
L. major genes were amplified by PCR from genomic DNA isolated from promastigotes
(reference strain MHOM/IL/80/Friedlin, zymodeme MON -103) using the DNeasy Tissue
Kit (Qiagen). Mouse MIF was amplified from mouse cDNA prepared by Dr Peggy
Shelbourne (Glasgow University) using whole brain tissue from C57BL/6J mice.
N-terminally his-tagged recombinant LmjF33.1740 (LmjMIF1) and LmjF33.1750
(LmjMIF2) were amplified using the following pairs of oligonucleotide primers containing
artificial restriction sites (underlined): OL1820 NdeI (5′
GCATATGCCGGTCATTCAAACGTTTG) with OL1821 XhoI (5′
GGCTCGAGTTAGAAGTTTGTGCCATTCCAG) and OL 1822 NdeI (5′
GGCATATGCCGTTTCTGCAGACGATTG) with OL 1823 XhoI (5′
GGCTCGAGTCAAAAGTTAGTGCCGTTCCAG). The products were cloned into the
Ndel/XhoI sites of pET28a (Novagen) to generate plasmids pGL1320 and pGL1319,
respectively.
C-terminally his-tagged recombinant LmjMIF1, LmjMIF2 and mouse MIF (mMIF,
Accession No. NM_010798) were amplified using the following pairs of oligonucleotide
primers containing artificial restriction sites (underlined): OL1820 with OL 2062 XhoI (5′
GGCTCGAGGAAGTTTGTGCCATTCCAG), OL1822 with OL 2063 XhoI (5′
GGCTCGAGAAAGTTAGTGCCGTTCCAG) and OL 2230 Nde1 (5′
CATATGCCTATGTTCATCG) with OL2231 XhoI (5′
CTCGAGAGCGAAGGTGGAACCG). The products were cloned into the NdeI/XhoI sites
of pET21a (Novagen) to give plasmids pGL1504, pGL1505 and pGL1574, respectively.
P1G mutants were made in accordance with the QuikChange® Site-Directed Mutagenesis
Kit (Stratagene) with pGL1504 and pGL1505 as template DNA and the following pairs of
degenerate (underlined) primers: OL2070
(CCTCAGCGAAAATGGGGGTCATTCAAACG) with OL2071
(CGTTTGAATGACCCCCATTTTCGCTGAGG) to create pGL1506 (LmjMIF1P1G) and
OL2072 (CCCACCTAAGAAAATGGGGTTTCTGCAGACG) with OL2073
(CGTCTGCAGAAACCCCATTTTCTTAGGTGGG) to create pGL1507 (LmjMIF2P1G).
The LmjMIF locus including flanking regions was amplifiied using the following pair of
oligonucleotide primers containing artificial restriction sites (underlined): OL2033 Not1 (5′
GCGGCCGCGCGCCACCCCAATAG) and OL 2003 Xho1
(AGATCTAAGGATGCAATTATGTAG) and PFx50™ polymerase (Invitrogen) and cloned
into the pRIB expression vector (34) to give pGL1540. All plasmids were sequenced in both
directions, to confirm the integrity of the constructs.
Recombinant protein expression and purification
Plasmids were transformed into BL21(DE3) cells for recombinant protein expression.
Recombinant LmjMIF and mouse MIF were induced with IPTG (1 mM) at 30°C and 37°C,
respectively. Cells were grown in 1 L cultures and the induced protein expression continued
overnight. Following cell lysis by sonication in 20 mL of NaH2PO4/300 mM NaCl pH 8.0
containing 10 μg mL−1 DNAase and 100 μg mL−1 lysozyme, the supernatant was filtered
and recombinant proteins purified using Nickel chelate chromatography followed by
desalting and HQ ion exchange chromatography. Proteins were concentrated to ~13 mg
mL−1 and stored in 50 mM Tris, 5 mM EDTA pH 7.0 at 4°C for up to 3 months without loss
of activity.
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Crystallisation
Crystals were grown by the hanging drop, vapour diffusion method in 24-well Linbro plates.
Crystals of LmjMIF1 grew in 3-5 days to a maximum size of 0.2 × 0.2 × 0.4 mm at 290 K
under the following conditions: the well contained 30% (w/v) PEG 4000, 100 mM imidazole
pH 6.5 and the drop contained 2 μL of protein solution at 13 mg mL−1 plus 2 μL of well
solution. Hexagonal plate-like crystals of LmjMIF2 grew at 290 K in drops containing 2 μL
of protein at 17 mg mL−1 and 2 μL of well solution, consisting of 29% (w/v) PEG 4000 and
100 mM Hepes, pH 7.5. Prior to data collection, crystals were flash frozen in liquid nitrogen
directly from the well solution.
X-ray data collection and structure determination
All data were collected on beamline BM14 at the ESRF (Grenoble, France) on a MAR CCD
detector using a  scan with a step size of 1°. Data indexing was performed using Mosflm
and the merging and scaling was carried out with SCALA (35). Data statistics are shown in
Table 1. Molecular replacement was performed with the program MOLREP (within the
CCP4 software suite (35)) using the structure of Xenopus laevis MIF (PDBID:1UIZ) as the
search model - it has 26% and 28% sequence identity to LmjMIF1 and LmjMIF2,
respectively. Structure building and refinement was performed using COOT (36) and
Refmac, respectively.
Enzyme assays
Tautomerase activity was assayed as previously described (37). All reactions were carried
out in a total volume of 800 μl at 37°C. The tautomerase substrate L-dopachrome methyl
ester was generated by adding 48 μL of L-dopa methyl ester (10 mM) and 32 μL of sodium
periodate (20 mM) to an appropriate volume of 10 mM sodium phosphate (pH 6.2) with 1
mM EDTA. For inhibition assays, 10 μL of ISO-1 (10 mM, Merck Biosciences, UK) or
DMSO was also added. The spontaneous decay of L-dopachrome methyl ester was
measured by absorbance (λ474 nm) using a Hewlett Packard 8453 UV/Visible
spectrophotometer for 30 s prior to the addition of recombinant protein. Specific activity
was determined using ε = 3700 M−1 cm−1.
MIF oxidoreductase activity was assayed in 200 mM sodium phosphate (pH 7.2) with 0.5
mg mL−1 insulin and 20 mM glutathione (Sigma, UK) at 37°C. Mouse MIF, LmjMIF1 and
LmjMIF2 (200 μg) were added and reduction of insulin was measured by the increase of
absorbance (λ650 nm) using a Hewlett Packard 8453 UV/Visible spectrophotometer. The
rate of reduction by MIFs was found relative to the intrinsic rate of insulin reduction by
glutathione (control).
Antibodies and Western analyses
Purified recombinant LmjMIF1 and LmjMIF2 were used to raise antisera in rabbits.
Antibodies were purified from sera using recombinant protein immobilized onto AminoLink
Plus coupling gel (Pierce). Leishmania cell pellets from all life cycle stages were lysed in
2% SDS containing protease inhibitor cocktail (Boehringer), protein concentration was
determined by Bradford Assay and extracts stored at −20°C until required. Samples
containing 10 μg of total protein were prepared using 4 x sample buffer and water, to
equalise loading volumes, prior to incubation at 95°C for 4 min to denature the protein.
Polyacrylamide electrophoresis was performed using a 12% gel run at 200V for ~45 min in
NuPAGE™ MES running buffer. Proteins were transferred to a nitrocellulose membrane
and detected using primary antibody diluted 1 in 1000 in TBST, secondary anti-rabbit IgG
coupled to HRP conjugate (Santa Cruz Biotechnology) and chemiluminescent substrate
(Pierce).
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Generation of transgenic L. braziliensis
Plasmid pGL1540 was digested with Pme1/Pac1, to remove the integration cassette which
was gel purified. Transfections were carried out using a human T-cell Amaxa nucleofector
kit (Amaxa Biosystems) according to the manufacturer’s protocol. 5 × 107 mid-log phase L.
braziliensis were harvested at 1000 × g for 10 min and resuspended in 100 μL of buffer for
Human T-cells and electroporated with 10 μg of the purified pGL1540 DNA using the U-33
programme before being transferred to 10 mL of fresh HOMEM medium with 10% (v/v)
HIFCS. 10 mL cultures were split into two 5 mL cultures to select for independent
transfection events and incubated at 25°C overnight. The following day, puromycin was
added to a final concentration of 50 μg mL−1 and serial dilutions were performed to select
for transfected clones. Cells were plated out in 96-well plates and incubated at 25°C.
Macrophage infection assays
Peritoneal macrophages form BALB/c mice were collected following injection of 5 mL of
ice-cold RPMI 1640-medium into the peritoneal cavity and gentle massage. Macrophages
were counted and re-suspended at a density of 5 × 105 cells mL−1 in RPMI supplemented
with 10% (v/v) HIFCS. 100μL of macrophage suspension were added to each well of a 16-
well Lab-tek™ cavity slide (50k m /well) and incubated at 37°C, 5% CO2 overnight. Cells
were washed and incubated with stationary phase promastigotes at a 10:1 ratio for 24hrs at
37°C. Later time points were given fresh media every 24 hours and incubated as before.
After incubation, slides were fixed with 70% methanol, Geimsa stained and the number of
infected cells determined by visualization under a light microscope.
RESULTS and DISCUSSION
Sequence alignments and phylogenetic reconstruction
A phylogenetic tree of evolutionary relationships was generated from the multiple sequence
alignment of 60 MIF-like proteins using a neighbour-joining algorithm (Figure 1A). This
tree was highly parsimonious with known evolutionary relationships. Strong clades delineate
along known taxonomic lines, the main clusters being cyanobacteria, nematodes,
vertebrates, apicomplexans (with Giardia) and plants. A strong association is seen between
MIFs from L. major, L. infantum and L. mexicana and gram positive bacteria belonging to
the genera Bifidobacterium and Clostridium. L. braziliensis was found not to contain intact
MIF1 or MIF2 genes (see below). The broad taxonomic distribution of MIF-like genes is
indicative of the ancient lineage of these proteins. It also appears that gene deletion events
are common for this family, for example MIF-like proteins are common in nematodes but
there are none in Drosophila melanogaster. However, the presence of the Leishmania MIFs
in a paraphyletic cluster, showing a strong association with bacterial MIF-like proteins, is
the only example of such an association in the analysis; this may be indicative of a lateral
gene transfer event (38).
Leishmania often have tandem repeats of genes that serve to increase the ultimate expression
of encoded proteins (38). On initial analysis it appeared that in L. major the two tandem
copies of MIF were an example of this, however, they are likely to be two independent
genes (LmjMIF1 and LmjMIF2) that have undergone distinct directional selection
subsequent to a gene duplication event. The presence of two MIFs in Leishmania is unusual
in that with the exception of some nematode species MIF orthologues are found as a single
copy, suggesting unique functions for these proteins. The L. major, L. mexicana and L.
infantum genomes contain MIF1 and MIF2-like genes that have 96-99% and 95-96% amino
acid identity, respectively. MIF1 and MIF2 sequences within a species have ~58% amino
acid identity to each other, and each has ~20% identity with mouse MIF. Alignment of the
sequences of LmjMIF1, LmjMIF2 with Brugia malayi, human and mouse MIF proteins
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(Figure 1B) reveals the conservation in LmjMIFs of the essential N-terminal proline residue
and a GKP motif (residues 32-34) involved in the tautomerase active site (39). The proline
of the GKP motif is replaced by Ser in the gram positive bacteria MIF sequences (Figure
1B). The CxxC motif, implicated in oxidoreductase activity of the human enzyme (residues
55 to 59) (31), is not found in either of the LmjMIFs.
LmjMIF1 has tatutomerase activity, LmjMIF2 is inactive
Recombinant LmjMIF1 and LmjMIF2 were produced with either N- or C-terminal histidine
tags. Recombinant N-terminal his-tagged LmjMIF1 and LmjMIF2 lacked enzymatic
activity, so C-terminal his-tagged proteins were used for enzyme assays. LmjMIF1
demonstrated a tautomerase activity that was 26-fold lower than that of mouse MIF (Table
2), whereas LmjMIF2 was unable to tautomerase L-dopachrome methyl ester. The specific
activity of LmjMIF1 (0.36 mM min−1 μM−1) compares with a previously reported value of
3.35 mM min−1 μM−1 for human MIF (28). Mutation of the catalytic proline of LmjMIF1 to
a glycine (LmjMIF1P1G) ablated tautomerase activity (Table 2). Mouse MIF tautomerase
activity was completely inhibited by 1.25 mM ISO-1 (IC50=10.5 μM), however LmjMIF1
tautomerase activity was unaffected by this concentration of inhibitor. Mouse MIF has
oxidoreductase activity (31) and LmjMIF1 has a small, but detectable activity, whilst no
oxidoreductase activity was detected with LmjMIF2 (Supplementary data 4). The absence of
this activity is not surprising given that the LmjMIFs do not contain the CxxC motif required
for mammalian oxidoreductase activity. The low level of activity shown by LmjMIF1 may
be due to the presence of a cysteine residue, absent in LmjMIF2, located in the vicinity of
the CxxC motif (Figure 1B). Bacterial orthologues of mammalian MIFs also lack the CxxC
motif and it is likely that oxidoreductase activity evolved during the evolution of MIFs in
eukaryotes.
Crystal structures of LmjMIF1 and LmjMIF2
Crystal structures of three LmjMIF1 and LmjMIF2 proteins have been determined:
LmjMIF1 with an N-terminal hexa-his tag (N-His-LmjMIF1) to 1.8 Å resolution, LmjMIF2
with an N-terminal hexa-his tag (N-His-LmjMIF2) to 1.9 Å resolution and LmjMIF1 with a
C-terminal hexa-his tag (C-His-LmjMIF1) to 2.6 Å resolution. Data collection and
refinement statistics are given in Table 1. All three structures were solved using molecular
replacement with a model based on the structure of Xenopus MIF (1UIZ) which, of the
structures solved, has the closest amino acid sequence identity (28.9 % and 28.4 %) to the L.
major sequences. The LmjMIF proteins adopt a trimeric ring architecture (Figure 2A,B)
similar to the other known MIF structures (Figure 2C) with each monomer composed of a 4-
stranded mixed β-sheet and two α-helices stacked against the β-sheet on the outside of the
trimer.
The recently published structure of LmjMIF1 (28) has a hexagonal unit cell with dimensions
a=b=52.32 Å, c=96.82 Å which is closely isomorphous with the N-His-LmjMIF1 crystal
form obtained in this work (a,b=52.32Å, c=97.94Å). No interpretable electron density for
the N-terminal tag was found in this structure. A least squares fit of the refined structure of
N-His-LmjMIF1 gave an r.m.s.d. for all residues of 0.4 Å. Thus, despite different
crystallisation conditions and different expression constructs, it appears that the two
structures are essentially identical. The C-His-LmjMIF1 construct, used for enzymatic
assays, was also found to adopt an essentially identical trimeric structure with r.m.s.d. fits
for the complete trimer to 3B64 (28) of 0.4 Å and N-His-LmjMIF of 0.6 Å. (Figure 2D).
LmjMIF1 and LmjMIF2 have structural differences
N-His-LmjMIF2 shows some structural features that differ subtly from N-His-LmjMIF1.
Individual chains of the LmjMIF1 and LmjMIF2 monomers can be superimposed with an
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r.m.s.d. of 0.9 Å for all Cα atoms and differ only in the conformation of residues 30 to 37
(30VLGKPEDL37 in LmjMIF1 and 30ELGKPEDF37 in LmjMIF2), which link the C-
terminal end of the first helix α1 with the second strand (β2) of the 4-stranded sheet. This
linker loop contains the active site residue K33 within the conserved GKP motif. In
LmjMIF1, the four residues 34PEDL37 form a β-turn (Figure 2E) while in LmjMIF2 a turn-
like conformation is adopted by the four residues 33KPED36 (Figure 2F). In the N-His-
MIF1 and 3B64 structures, the conformation of this motif which locks the side chain of K33
in the vicinity of the P1 is in part determined by salt bridges between R24 and D36 and R28
and E35, where R24 and R28 lie in the middle of α1 and are separated by one turn of the
long helix. These residues are conserved among the Leishmania MIFs, except LmMIF2
where there is an R24G mutation. The LmjMIF2 structure accommodates the removal of
such a large side chain, which abuts the 4-stranded sheet by partially filling this space with
the side chain of F37. The significant conformational change in this conserved sequence
places K33 away from P1, which has a likely adverse affect on the mechanism (see below).
The structural analysis is complicated in this instance by the presence of N-terminal His-tag
residues attached to P1. However modelling shows that these residues would not prevent the
31LGKPED36 motif adopting the same conformation as found in the LmjMIF1 structures
and that the likely driver for the conformational change (and loss of tautomerase activity) is
the R24G difference in sequence.
LmjMIF structures differ in two key regions from all other MIF structures
Comparison of the trimer structures of LmjMIF1 and LmjMIF2 with MIF structures from
the other available species shows that both LmjMIF1 and LmjMIF2 are the most distinct. A
least squares fit using α-carbons from all three chains in the trimer gives r.m.s.d values of
around 4Å against the vertebrate (200W, 1MFF, 1FIM) and helminth (1HFO) structures.
The r.m.s. fit among these vertebrate and helminth trimer structures is only around 1Å. It is
also worth noting that the these rms deviations are almost the same whether individual
chains (about 110 C-α atoms) or the complete trimer of 330 C-α atoms are used for the fit.
This suggests that there is no inter-domain flexibility in the trimer as can be found in other
homo-oligomeric enzymes, e.g. pyruvate kinase (40).
A comparison of LmjMIF2 with mammalian MIF (2OOW and 1MFF) identified two
regions with structural differences. The first helix (α1) extends from residues 13 to 31 in
both LmjMIF structures while it is significantly shorter in all structures from other species
(Figure 3). In mouse and human, for example, α1 extends from residues 18 to 30. All MIF
structures from mammalian and invertebrates also have a short η1 helix (residues 10-14)
with a conserved Pro15 acting as a helix breaker between η1 and α1; this is located on the
bottom face of the trimer, distal from the tautomerase active site. There is a conserved
change in sequence in the L. major MIFs (Pro15Lys) and a concomitant disappearance of η1
and lengthening of α1. The change in helix length has a quite significant effect on the
position of α1 in the L. major structures relative to the other MIF structures (Figure 4A). It
is likely that this change in helix position is a major contributor to the rather poor r.m.s. fit
between LmjMIFs and the other structures.
The second region of the LmjMIFs that differs significantly from all other MIF structures is
on the top surface of the trimer close to the tautomerase active site and comprises the loop
between residues 64 and 71 (which joins the strand β4 with the second long helix α2) and
residues 100 to107 which continue from strand β5 (Figure 3B). The sequence of the 64-71
loop differs in the two L. major proteins (64ALGGYGPS71 in LmjMIF1 and
64SWGEYAPS71 in LmjMIF2) but they have similar conformations. However, an overlay
of the 64-71 loop from the L. major and mouse MIF structures shows that corresponding
main chain atoms are over 6 Å apart. An active site residue at the beginning of this loop
(Ile64 in mouse MIF, Leu65 in LmjMIF1 and Trp65 in LmjMIF2) plays an important role in
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substrate recognition and is shifted away the active site in the LmjMIF2 structure. Most
64-71 loops (with the notable exception of LmjMIF2) have a total of three Gly residues
within this short sequence, and Gly66 is absolutely conserved through all MIF sequences
implying that flexibility of the loop is important for either substrate recognition or enzymatic
activity. Strand β5 is extended in the L. major MIFs compared to other MIFs and the
sequence continues into strand β6 (residues 103 to 107) whereas a turn (η4) forms in
mammalian MIFs (Figure 3B). This difference in conformation leads to a narrower pore on
the top face of the trimer in the L. major MIFs.
A comparison of the electrostatic surfaces (Figure 4) shows the mammalian MIFs have a
very positively charged top trimer face, which is similar to LmjMIF2. This contrasts with
the predominantly negative surface of LmjMIF1. These images also highlight the central
hole in the MIF trimer, which has a rather variable size depending on sequence. The
hydrophobic hole of the human MIF is large enough to accept an extended hydrocarbon
chain, such as a lipopolysaccharide (LPS) molecule (8). It is less likely that such an
interaction is relevant to the biology of Leishmania – and indeed the hole in the LmjMIF
trimer provides a less good fit for LPS.
The tautomerase active site
The keto-enol tautomerase active site of mouse MIF is formed by Pro1, Lys32 and Ile64 of
one monomer and Tyr95 and Asn97 of the adjacent monomer (39). The N-terminal Pro1 is
the general base catalyst in the reaction and Lys33 plays a role in lowering the pKa of this
residue as well as binding the substrate (39). These two residues are conserved in the L.
major MIFs, and their positions are also conserved in the LmjMIF1 structure (Table 3,
Figure 2A). However in LmjMIF2 the different conformation of the turn spanning L31-D36
displaces the side-chain of Lys33 away from the active site, thus affecting its catalytic role
(Figure 2B). The change in the active site structure of LmjMIF2 may affect the entry of the
substrate to the ligand binding pocket.
The third tautomerase active site residue of both LmjMIF1 and LmjMIF2 (L65 and W65,
respectively) have subtly different positions compared with the equivalent residue in mouse
MIF (I64), due to the different conformation of the loop formed by residues 64 to 71 and the
presence of β6 in place of η4. The fourth and fifth active site residues are not essential for
mouse MIF tautomerase activity: the mutants Y95F and N97A had no effect on activity (41),
but the latter showed reduced inhibitor binding affinity. N97 is replaced by hydrophobic
residues in the L. major MIFs (Table 3) which would be unable to form stabilising hydrogen
bonds with a substrate. Moreover, the bulky side-chain of F98 in LmjMIF2 may reduce the
size of the active site. Resolution of the LmjMIF tertiary structures thus reveal subtle but
potentially significant structural differences not only between mammalian MIF and the
LmjMIFs but between the individual parasite proteins, which may explain the observed
differences of LmjMIF enzyme activities.
LmjMIF1 has significantly less tautomerase activity than mouse MIF and LmjMIF2 was
inactive. L-dopachrome, however, is not a physiological substrate of MIFs and so inability
to utilise it as a substrate does not provide definitive evidence for LmjMIF2 being inactive.
Nevertheless, this is highly indicative of the two LmjMIFs having differential substrate
specificities. It is also interesting to note that ISO-1, an inhibitor of mammalian MIF, does
not inhibit LmjMIF1, thus suggesting that there may be opportunity to design MIF species-
specific inhibitors.
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Species- and stage-specific expression of MIF1 and MIF2
Analysis of the L. braziliensis genome (www.genedb.org) indicates that this species lacks
intact MIF genes. To confirm this, the MIF locus was PCR amplified from the genome strain
(L. braziliensis M2904) and sequenced. This showed that the region around the MIF locus
had maintained synteny with the other Leishmania species (Figure 5A), but that the MIF
genes had undergone a process of pseudogene formation. MIF1 is truncated by a frame shift,
while a deletion has removed the start codon for MIF2 (Figure 5A). This was confirmed by
western blot analysis (Figure 5B, lane 2) as neither MIF1 nor MIF2 could be detected in
protein extracts from L. braziliensis promastigotes with anti-MIF antibody, although the
antibodies detected L. mexicana and L. infantum MIF1 and MIF2 (data not shown).
Affinity purified rabbit anti-LmjMIF1 antibody was found to be specific for LmjMIF1
(Figure 5C, lane 1) as it does not react with recombinant LmjMIF2 (rLmjMIF2), lane 2). In
contrast, the anti-LmjMIF2 antibody displays some cross reactivity as it recognises
rLmjMIF1 and rLmjMIF2 (Figure 5C, lanes 1 and 2, lower panel). LmjMIF1 was only
expressed in L. major amastigotes (Figure 5C, lane 5) while LmjMIF2 was expressed during
all the life cycle stages analysed namely procyclic promastigote, the flagellated replicative
form of the parasite found in the abdominal midgut of the sandfly; metacyclic promastigote,
the mammalian infective form found in sandfly mouth parts and intracellular amastigote,
resident in mammalian host macrophages (Figure 5C, lanes 3-5). The stage-specific
expression pattern of the LmjMIFs is a further indication that they have different biological
roles.
When LmjMIF1 and LmjMIF2 were introduced into the ribosomal locus of L. braziliensis,
expression of both MIF proteins could be detected by western blot in the promastigote life
cycle stage (Figure 5B, lanes 3, 4 and 5). To test if expression of L. major MIF genes in L.
braziliensis influenced the ability of the parasites to infect host cells, a macrophage infection
assay was performed. This showed that the combined expression of both LmjMIFs in L.
braziliensis increased the level of infection by 20% in comparison to wild type L.
braziliensis (Figure 5D). It did not, however, increase the ability of the parasites to survive
within macrophages as levels of infection of the transgenic parasites declined in line with
wild type L. braziliensis by day 5 of the infection. While the absence of MIF from L.
braziliensis shows that MIF is not required for infection in all Leishmania species, it
highlights the intriguing possibility that Leishmania MIFs have a role in disease tropism or
may contribute to disease severity and outcome in conjunction with a host’s own immune
responses (42). Host genetics and in particular IL-6 (43) and IL-10 (44) polymorphisms are
associated with mucosal and both mucosal and cutaneous leishmaniasis respectively and
studies have linked regions on human chromosomes 15 and 19 with protection from visceral
leishmaniasis (45). Parasite genetics also contribute to the clinical outcome of leishmaniasis
and levels of protein expression can significantly alter tissue tropism and disease severity
(46).
Perspective
More studies involving immunological analyses using transgenic parasites are required to
determine the role of MIF proteins in L. major, but it seems likely that at least the
amastigote-specific MIF1 is involved in host-parasite interactions. This is a hypothesis
further strengthened by the recent publication of the L. donovani promastigote ‘secretome’
(47). The secretome consists of parasite proteins that are actively secreted from L. donovani
promastigotes, this clearly misses amastigote-specific proteins – which accounts for the
absence of LdMIF1. However LdMIF2 was identified, which is consistent with a role in the
insect infective stages of the parasite.
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Although the exact role of mammalian MIF in inflammation and immune response is
currently controversial, it is increasingly evident that some intracellular parasites, including
Plasmodium, have MIF-like proteins that are likely to be involved in immune invasion and
can be detected in host sera (48). This physical characterisation of the LmjMIF proteins has
shown that they are structurally, biochemically and temporally capable of contributing to
Leishmania parasite persistence. Further in vivo biological analysis is underway to elucidate
their precise roles.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Sequence alignments and phylogenetic reconstruction
(A) An unrooted neighbour-joining phylogenetic tree of MIF protein sequences. For clarity,
the clade containing Leishmania sequences has been shown in detail. A full phylogram
including percentage bootstrap values is included in supplementary data 4. (B) Alignment of
the sequences of MIF-like proteins from Leishmania major, Bifidobacterium longum,
Clostridium acetobutylicum, Brugia malay, human and mouse. Conserved residues are
highlighted by a red background and similar residues are indicated by red text and boxed in
blue. The secondary structure elements of Leishmania MIF1 and mouse MIF are shown
above and below the sequence alignments respectively.
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Figure 2. Structures of Leishmania major MIF1 and MIF2
(A) LmjMIF1 trimer, (B) LmjMIF2 trimer and (C) mouse MIF in cartoon representation;
catalytic residues are highlighted by sticks. (D) An overlay of a monomer of LmjMIF1 with
a N-terminal hex-His tag (magenta) and a C-terminal tag with the secondary structure
elements labelled. (E) Close up of the tautomerase active site of LmjMIF1 showing the
catalytic residues Pro1 and Lys33, the β turn formed by residues Pro34-Leu37 and the salt
bridges between Arg24 and Asp36, and between Arg28 and Glu35 (F) The tautomerase
active site of LmjMIF2. The alternative conformation of the linker region Glu30-Phe37,
which contains the conserved GKP motif, removes Lys 33 from the active site.
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Figure 3.
(A) Leishmania MIFs have an extended α-1 helix compared with mouse MIF (B) The 64-71
loop has inherent flexibility and residues 100-107 form a β-strand in LmjMIFs but a η-helix
in mouse MIF.
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Figure 4.
Electrostatic potential surfaces of the Leishmania MIF and the mouse MIF structures.
Positive charge is indicated in blue whereas red indicates negative charge. The views from
the top and bottom of the trimers are shown in (A) and (B) respectively.
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Figure 5. Expression of MIF in Leishmania
(A) Schematic representation of the MIF locus in L. major (LmjF) L. infantum (LinJ) and
L. braziliensis (LbrM). Grey arrows represent intact MIF genes. Pseudo MIF locus in LbrM
shows nucleotides present in LmjF and LinJ but missing from LbrM in lower case and
underlined. (B) Western blot of L. major, L. braziliensis and L. braziliensis clones
expressing LmjMIF1 and LmjMIF2 probed with anti-MIF1 and anti-MIF2 antibodies. (C)
Western blot of rLmjMIF1 or rLmjMIF2 (50 pg each) or whole cell lysates from L. major
multiplicative promastigotes, metacyclic promastigotes and amastigotes (10 μg each). (D) L.
braziliensis WT:MIF1-2 Clone 1 (C1) and 3 (C3) were used to transfect BALB/c
macrophages at a 10:1 ratio and infectivity was measured by Giemsa staining and counting
under a light microscope 1, 3 and 5 days post-infection. The data are means +/− SD from
three independent experiments.
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Table 1
X-ray diffraction data and refinement statistics
Crystal LmjMIF1
(N-terminal His6 tag)
LmjMIF1
(C-terminal His6 tag)
LmjMIF2
(N-terminal His6 tag)
Space group H3 P2(1) P6(3)22
Cell dimensions a,b=52.32Å,
c=97.94Å
α=β=90°, γ=120°
a=39.1Å, b=84.2Å
c=48.2Å, α=γ=90°,
β=109.8°
a,b=53.96Å,
c=138.9Å
α=β=90°, γ=120°
Mosaicity 0.45 0.89 0.50
Molecules per ASU 1 3 1
Matthews Coeff. (Å3Da−1) 1.76 1.99 1.95
Solvent (%) 30.8 38.4 37.1
Resolution (Å) 25-1.8 (1.9-1.8) 39.9-2.6 (2.74-2.6) 38.8-1.9 (2.0-1.9)
R(merge) 0.069 (0.121) 0.164 (0.674) 0.089 (0.362)
Total no. of reflections 52481 (4357) 33734 (4970) 105380 (11582)
No. of unique reflections 9160 (1242) 9130 (1333) 10155 (1430)
<I>/σI 20.9 (7.2) 8.6 (1.9) 21.2 (5.7)
Completeness % 98.8 (93.4) 99.9 (100.0) 100.0 (100.0)
Multiplicity 5.7 (3.5) 3.7 (3.7) 10.4 (8.1)
R/R(free) 0.192/0.255 0.250/0.327 0.228/0.278
Average B factor 18.18 35.1 21.50
Rmsd Bond 0.021 0.019 0.021
Angle 2.42 1.96 2.04
Chiral 0.123 0.120 0.185
Ramachandran core(%) 93.7 83.7 87.9
allowed (%) 5.3 14.3 10.1
generous (%) 1.1 2.0 2.0
disallowed (%) 0.0 0.0 0.0
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Table 2
Tautomerase activity of C-terminal His6 tagged MIF proteins. SEM is the standard error of the mean of three
replicates.
Protein Specific Activity (μmol s−1 mg−1)
+/− SEM
Mouse MIF 2011 +/− 270
LmjMIF1 76 +/− 3.2
LmjMIF1P1G <3
LmjMIF2 <3
LmjMIF2P1G <3
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Table 3
Tautomerase active site residues of mouse and L. major MIFs.
mMIF LmjMIF1 LmjMIF2
P1 P1 P1
K32 K33 K33
I64 L65 W65
Y95 F96 Y96
N97 L98 F98
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